AtaiBeckley’s BPL-003 Depression Data Sharpen Clinical Path And Investor Focus

AtaiBeckley (NasdaqGM: ATAI) reported peer reviewed Phase 2a results for its BPL-003 program in treatment resistant depression. The study showed a rapid and sustained antidepressant response from a ...

AtaiBeckley’s BPL-003 Shows Rapid, Durable Antidepressant Response in Treatment-Resistant Depression Patients on SSRIs; Phase 2a Data Published in CNS Drugs

Day 2 following a single intranasal dose of BPL-003 in both the 10 mg (n=6) and 12 mg (n=6) cohorts; Durable responses ...
The Currency Analytics

Bubble Protocol Surges 15% After ChainLink Oracle Partnership Deal

Bubble Protocol jumped hard Monday. The blockchain firm's native token BPL shot up 15% after announcing a strategic ...

AtaiBeckley reports rapid response in Phase 2a trial of depression drug BPL-003

AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) announced that patients in a mid-stage trial of its experimental depression ...

BPL-003 Phase 3 Program Initiation on Track for Q2 2026 Following Successful FDA End-of-Phase 2 Meeting; AtaiBeckley Highlights Key Pipeline Milestones at 2026 Investor Day

BPL‑003 holds Breakthrough Therapy Designation and is supported by positive Phase 2b results in treatment-resistant depressionCash runway reaffirmed through the planned early-2029 topline readouts ...

AtaiBeckley: 'Buy' On New Key Developments For BPL-003 For TRD

AtaiBeckley is well-capitalized with $220.7M in cash, sufficient to fund operations into 2029 and progress multiple TRD and ...
The Caledonian-Record

AtaiBeckley’s BPL-003 Shows Rapid, Durable Antidepressant Response in Treatment-Resistant ...

Day 2 following a single intranasal dose of BPL-003 in both the 10 mg (n=6) and 12 mg (n=6) cohortsDurable responses observed ...